Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Owen · SciRah

Researcher profile · Semantic Scholar

C. Owen

Share profile

C. Owen — researcher profile on SciRah

h-index: 36
Works: 163
Citations: 10K

Most-cited papers

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. Woyach, A. Ruppert, N. Heerema, Wei-Qiang Zhao +27 more
2018New England Journal of Medicine830 citations Open access
Semantic Scholar
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. Seymour, T. Kipps, B. Eichhorst, P. Hillmen +16 more
2018New England Journal of Medicine806 citations Open access
Semantic Scholar
Obinutuzumab for the First‐Line Treatment of Follicular Lymphoma
R. Marcus, A. Davies, K. Ando, W. Klapper +14 more
2017New England Journal of Medicine701 citations Open access
Semantic Scholar
Long-Term Efficacy and Safety of First-Line Ibrutinib Treatment for Patients With CLL/SLL: 5 Years of Follow-Up From the Phase 3 RESONATE-2 Study
J. Burger, P. Barr, T. Robak, C. Owen +15 more
2019Leukemia423 citations Open access
Semantic Scholar
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
A. Kater, J. Seymour, P. Hillmen, B. Eichhorst +11 more
2019Journal of Clinical Oncology276 citations Open access
Semantic Scholar
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
P. Barr, C. Owen, T. Robak, A. Tedeschi +15 more
2022Blood Advances253 citations Open access
Semantic Scholar
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
A. Kater, J. Wu, T. Kipps, B. Eichhorst +24 more
2020Journal of Clinical Oncology195 citations Open access
Semantic Scholar
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
A. Kater, C. Owen, Carol Moreno, G. Follows +17 more
2022NEJM Evidence186 citations
Semantic Scholar
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jeffrey A. Jones, T. Robak, Jennifer R. Brown, Farrukh T. Awan +13 more
2017The Lancet Haematology179 citations
Semantic Scholar
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
J. Seymour, T. Kipps, B. Eichhorst, J. D'Rozario +17 more
2022Blood142 citations Open access
Semantic Scholar
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
P. Barr, T. Robak, C. Owen, A. Tedeschi +17 more
2018Haematologica134 citations Open access
Semantic Scholar
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
J. Trotman, S. Barrington, D. Belada, M. Meignan +204 more
2018The Lancet Oncology125 citations Open access
Semantic Scholar
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
K. Fischer, O. Al-Sawaf, A. Fink, M. Dixon +23 more
2017Blood121 citations Open access
Semantic Scholar
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
W. Wierda, A. Rawstron, F. Cymbalista, X. Badoux +17 more
2021Leukemia78 citations Open access
Semantic Scholar
Ineffectiveness of high‐dose methotrexate for prevention of CNS relapse in diffuse large B‐cell lymphoma
R. Puckrin, Haidar El Darsa, Sunita Ghosh, A. Peters +2 more
2021American journal of hematology/oncology69 citations
Semantic Scholar
Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study
R. Marcus, A. Davies, K. Ando, W. Klapper +14 more
201662 citations
Semantic Scholar
Germline variants drive myelodysplastic syndrome in young adults
Simone K Feurstein, J. Churpek, T. Walsh, S. Keel +31 more
2021Leukemia58 citations Open access
Semantic Scholar
Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)
A. Kater, T. Kipps, B. Eichhorst, P. Hillmen +17 more
202058 citations
Semantic Scholar
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy
J. Woyach, A. Ruppert, N. Heerema, Wei-Qiang Zhao +23 more
2021Blood48 citations Open access
Semantic Scholar
The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy
Claire C. Homan, Sarah L. King-Smith, D. Lawrence, P. Arts +39 more
2021Haematologica40 citations Open access
Semantic Scholar
Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41
Claire C. Homan, M. Drazer, Kai Yu, D. Lawrence +61 more
2023Blood Advances36 citations Open access
Semantic Scholar
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
T. Munir, Carol Moreno, C. Owen, G. Follows +21 more
2023Journal of Clinical Oncology35 citations Open access
Semantic Scholar
Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study
J. Seymour, T. Kipps, B. Eichhorst, P. Hillmen +16 more
201734 citations
Semantic Scholar
Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
J. Seymour, T. Kipps, B. Eichhorst, P. Hillmen +17 more
2019Blood23 citations Open access
Semantic Scholar
Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies
T. Robak, J. Burger, A. Tedeschi, P. Barr +22 more
2018American journal of hematology/oncology23 citations Open access
Semantic Scholar
First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study
Tahla Munir, Carol Moreno, C. Owen, G. Follows +18 more
2021Blood22 citations Open access
Semantic Scholar
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202
J. Woyach, A. Ruppert, N. Heerema, Wei-Qiang Zhao +22 more
2018Blood22 citations
Semantic Scholar
Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia
P. Johnson, J. Woyach, Angela Ulrich, Veronique Marcotte +18 more
2023Journal of Geriatric Oncology19 citations Open access
Semantic Scholar
Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study
R. Harrup, C. Owen, J. D'Rozario, T. Robak +9 more
202019 citations Open access
Semantic Scholar
Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study
S. Barrington, J. Trotman, D. Şahin, D. Belada +11 more
2018Blood19 citations Open access
Semantic Scholar
Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
P. Barr, C. Owen, T. Robak, A. Tedeschi +16 more
202118 citations
Semantic Scholar
Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update.
C. Owen, V. Banerji, Natalie Johnson, A. Gerrie +3 more
2023Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis17 citations Open access
Semantic Scholar
Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study
C. Niemann, T. Munir, Carol Moreno, C. Owen +20 more
2022Blood16 citations Open access
Semantic Scholar
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
A. Ruppert, Allison M. Booth, W. Ding, N. Bartlett +16 more
2021Leukemia16 citations Open access
Semantic Scholar
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients.
S. Sanders, N. Chua, J. Larouche, C. Owen +2 more
2019Biology of Blood and Marrow Transplantation15 citations Open access
Semantic Scholar
Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia
C. Owen, A. Christofides, N. Johnson, T. Lawrence +2 more
2017Leukemia and Lymphoma14 citations
Semantic Scholar
Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects
A. Trottier, Sonia Cerquozzi, C. Owen
2017Blood and Lymphatic Cancer : Targets and Therapy13 citations Open access
Semantic Scholar
Long‐term follow‐up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma
R. Puckrin, N. Chua, K. Chin, A. Peters +6 more
2023British Journal of Haematology12 citations
Semantic Scholar
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
A. Chatterjee, G. van de Wetering, R. Goeree, C. Owen +4 more
2022PharmacoEconomics - Open12 citations Open access
Semantic Scholar
Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years
P. Ghia, C. Owen, J. Barrientos, P. Barr +6 more
2022Blood11 citations Open access
Semantic Scholar
A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies
C. Owen, S. Robinson, A. Christofides, L. Sehn
2022Current Oncology11 citations Open access
Semantic Scholar
MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
J. Seymour, T. Kipps, B. Eichhorst, P. Hillmen +17 more
2018Blood11 citations Open access
Semantic Scholar
Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada
J. Lachaine, K. Guinan, A. Aw, V. Banerji +2 more
2023Current Oncology10 citations Open access
Semantic Scholar
Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada
J. Lachaine, C. Beauchemin, K. Guinan, P. Thebault +4 more
2021Current Oncology10 citations Open access
Semantic Scholar
Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.
C. Owen, A. Gerrie, V. Banerji, S. Assouline +4 more
2018Current Oncology9 citations Open access
Semantic Scholar
Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in Older Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia Treated With Ibrutinib (Ibr): 3-Year Follow-up of the RESONATE-2 Study
A. Tedeschi, C. Owen, T. Robak, P. Barr +18 more
20179 citations
Semantic Scholar
Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison
T. Robak, J. Burger, A. Tedeschi, P. Barr +22 more
20178 citations
Semantic Scholar
Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia.
C. Owen, Sarah Eisinga, V. Banerji, Natalie Johnson +4 more
2023Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis7 citations Open access
Semantic Scholar
Allogeneic hematopoietic cell transplantation for Richter transformation of chronic lymphocytic leukemia: an intention-to-transplant analysis
R. Puckrin, C. Owen, A. Fontaine, A. Peters +2 more
2023Bone Marrow Transplantation6 citations
Semantic Scholar
Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41
Anna L. Brown, Claire C. Homan, M. Drazer, Kai Yu +60 more
2022Blood6 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Robak×19
Invite
T. Robak — researcher profile on SciRah
P. Hillmen×15
Invite
P. Hillmen — researcher profile on SciRah
A. Kater×13
Invite
A. Kater — researcher profile on SciRah
S. Coutre×12
Invite
S. Coutre — researcher profile on SciRah

×12

Invite

J. Seymour — researcher profile on SciRah

Invite

T. Kipps — researcher profile on SciRah

Invite

P. Barr — researcher profile on SciRah

Carol Moreno×10

Invite

Carol Moreno — researcher profile on SciRah

B. Eichhorst×9

Invite

B. Eichhorst — researcher profile on SciRah

Invite

M. Boyer — researcher profile on SciRah

Invite

P. Ghia — researcher profile on SciRah

J. D'Rozario×8

Invite

J. D'Rozario — researcher profile on SciRah